Intensity Therapeutics In...

NASDAQ: INTS · Real-Time Price · USD
0.61
-0.03 (-4.22%)
At close: Apr 29, 2025, 10:06 AM
-4.22%
Bid 0.61
Market Cap 8.29M
Revenue (ttm) n/a
Net Income (ttm) -16.27M
EPS (ttm) -1.17
PE Ratio (ttm) -0.52
Forward PE -0.65
Analyst Buy
Ask 0.62
Volume 63,657
Avg. Volume (20D) 115,427
Open 0.63
Previous Close 0.64
Day's Range 0.60 - 0.64
52-Week Range 0.50 - 5.28
Beta 4.59

About INTS

Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & D...

Industry Biotechnology
Sector Healthcare
IPO Date Jun 30, 2023
Employees 5
Stock Exchange NASDAQ
Ticker Symbol INTS
Full Company Profile

Advertisement

Analyst Forecast

According to 3 analyst ratings, the average rating for INTS stock is "Buy." The 12-month stock price forecast is $8.5, which is an increase of 1290.02% from the latest price.

Stock Forecasts
3 days ago
-37.14%
Intensity Therapeutics shares are trading lower af... Unlock content with Pro Subscription
4 months ago
-12.34%
Intensity Therapeutics shares are trading lower. The company presented final data from Intensity's INVINCIBLE-2 Study and an overview/update of the INVINCIBLE-4 Study.